Vulvar Cancer clinical trials at UCSF

1 research study open to eligible people

Vulvar cancer starts in the outer part of the female genitals. UCSF is conducting trials to see if nivolumab, alone or with cabozantinib, can stop mucosal melanoma from coming back after surgery. These studies help us find better treatments for vulvar cancer.

Showing trials for

  • Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

    open to eligible people ages 18 years and up

    This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving nivolumab in combination with cabozantinib could prevent cancer from returning.

    San Francisco, California and other locations

Our lead scientists for Vulvar Cancer research studies include .

Last updated: